Home › NDC Lookup › Ingredients › Bisacodyl › 57237-0337-21
Proctozone-B Bisacodyl 10 mg Suppository, 12 suppositories — NDC 57237-0337-21 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Proctozone-B Bisacodyl 10 mg Suppository, 12 suppositories — NDC 57237-337-21 (Billing 57237-0337-21)

by Rising Pharma Holdings, Inc. · 3 BLISTER PACK in 1 CARTON / 4 SUPPOSITORY in 1 BLISTER PACK

This is a package of 12 suppositories of Proctozone-B Bisacodyl 10 mg Suppository from Rising Pharma Holdings, Inc., marketed since Dec 2024 and currently FDA-listed; retail pharmacies pay about $0.3197 per suppositorie (NADAC).

NDC 57237-0337-21
🏷️ FDA NDC (as labeled) 57237-337-21 billing pads the product segment with a zero
This package
Contains12 suppositories Cost per ea$0.3197 NADAC Per package$3.84 / 12 suppositories Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.6082/unit — full pricing hub ↓
Product page 57237-0337-03 Also comes in: 30 suppositories 57237-337-03
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 57237-337-21 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
57237 labeler · 337 product · 21 package
Package marketed since
Dec 1, 2024
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
12 EA per package
Barcode (UPC-A, from the NDC)
3 5723733721 9
Medicaid fills, this package
2,671 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 57237-337-21
Product NDC 57237-337
11-digit billing NDC 57237033721
NCPDP billing unit EA — each (per item)
RxCUI 198509
UNII 10X0709Y6I
Application # M007.60
SPL Set ID c53ed934-3846-4dc8-b97b-c84171c21ae1
Established class (EPC) Stimulant Laxative
Physiologic effect Increased Large Intestinal Motility; Stimulation Large Intestine Fluid/Electrolyte Secretion
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2024-12-01
Route RECTAL
Dosage form SUPPOSITORY
Substance BISACODYL

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 46200010005205
GCN Seq No 002944
GCN 08731
HICL code 001301
Ingredient (HICL) Bisacodyl
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q3
Therapeutic class — intermediate (HIC2) Anal-Rectal Preparations
HIC3 code Q3S
Therapeutic class — specific (HIC3) Laxatives, Local/Rectal
AHFS code 56:12.00.00
AHFS class Cathartics And Laxatives
FDB label name PROCTOZONE-B 10 MG SUPPOSITORY
FDB brand name Proctozone-B
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 002944
  • GCN: 08731
  • GPI-14 (Medi-Span): 46200010005205
  • HICL (First Databank): 001301
  • AHFS class code: 56:12.00.00
  • RxCUI (RxNorm): 198509
Why two NDCs? The FDA registers this code as 57237-337-21 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 57237-0337-21. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Stimulant Laxative class.

Pharmacologic class Stimulant Laxative
Drug family (ATC) Contact laxatives, Enemas
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name PROCTOZONE-B 10 MG SUPPOSITORY Ingredient Bisacodyl
📗 Our plain-language guide HelloPharmacist
  • It relieves occasional constipation and irregularity. The Fleet enema is also used for fecal impaction and to clear residue after a barium test. It is meant for short-term use.
  • It depends on the form. Tablets usually work in 6 to 12 hours. Suppositories usually work in 15 minutes to 1 hour. The Fleet enema usually works in 5 to 20 minutes.
  • Not right away. Wait at least 1 hour after an antacid or milk before taking tablets. Swallow tablets whole with water and do not chew or crush them.
  • Can I take the tablets with an antacid or milk?
📖 Read our full Bisacodyl guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.320 $3.84 / 12 suppositories
Medicaid paysCMS SDUD · 12 mo $0.6082 $7.30 / 12 suppositories
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.369 $0.320
▼ Down 11% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
57237-0337-03 57237-337-03 Main listing 6 BLISTER PACK in 1 CARTON / 5 SUPPOSITORY in 1 BLISTER PACK $0.3197 / ea $9.59 2025-02-01 — Active
57237-0337-21 You're viewing this 3 BLISTER PACK in 1 CARTON / 4 SUPPOSITORY in 1 BLISTER PACK $0.3197 / ea $3.84 2024-12-01 — Active

This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($0.3197 NADAC).

This pack accounts for about 47% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 12 suppositories — 3 blister pack in 1 carton / 4 suppository in 1 blister pack.
How does this package differ from NDC 57237-0337-03?
Both are Proctozone-B Bisacodyl 10 mg Suppository — the drug itself is identical. This page's package is the 12 suppositories one, while NDC 57237-0337-03 is the 30 suppositories package.
What NDC number is used to bill for this package of Proctozone-B Bisacodyl 10 mg Suppository?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Bisacodyl 10 mg 00574-7050-12 Padagis 12 suppositories $0.320 — Availability likely —
Bisacodyl 10 mg 00904-7142-12 Major 12 suppositories $0.320 — Availability likely —
Good Neighbor Pharmacy Gentle Laxative 10 mg/2000mg 46122-0608-51 AmerisourceBergen 40 mg $0.320 — Availability likely —
Bisacodyl 10 mg 57237-0327-03 Rising 30 suppositories $0.320 — Availability likely —
Proctozone-B 10 mgthis 57237-0337-21 Rising 12 suppositories $0.320 — Availability likely —
Bisacodyl 10 mg 70000-0573-01 Cardinal 4 suppositories $0.320 — Availability likely —
Foster and Thrive Gentle Laxative 10 mg/2000mg 70677-1091-01 Strategic 40 mg $0.320 — Availability likely —
Walgreens Gentle Laxative 10 mg 00363-0466-04 Walgreens 40 mg — — FDA listed —
Walgreens Gentle Laxative 10 mg 00363-0468-04 Walgreens 4 suppositories — — FDA listed —
Rite-Aid Gentle Laxative 10 mg 11822-4890-05 RITE 8 suppositories — — FDA listed —
Gentle Laxative Bisacodyl 10 mg 13709-0321-01 NeilMed 30 capsules — — FDA listed —
Bisacodyl Laxative 10 mg/1.8g 13709-0328-01 Neilmed 1.8 g — — FDA listed —
HEB Gentle Laxative 10 mg/2000mg 37808-0877-08 H 40 mg — — FDA listed —
Dulcolax Laxative 10 mg 41167-0210-01 Chattem, 4 suppositories — — FDA listed —
Meijer Gentle Laxative 10 mg/2000mg 41250-0665-04 Meijer 40 mg — — FDA listed —
Discount Drugmart Gentle Laxative 10 mg/2000mg 53943-0805-08 Discount 40 mg — — FDA listed —
Dollar General Gentle Laxative 10 mg/2000mg 55910-0457-04 Dolgencorp, 40 mg — — FDA listed —
Bisacodyl 10 mg 57896-0443-01 GERI-CARE 100 suppositories — — FDA listed —
Stratuscare Bisacodyl 10 mg 58980-0415-04 Stratus 4 suppositories — — FDA listed —
CVS Gentle Laxative 10 mg 59779-0107-09 CVS 8 suppositories — — FDA listed —
Bisacodyl 10 mg 68016-0084-08 Pharmacy 8 suppositories — — FDA listed —
Bisacodyl 10 mg 69842-0816-04 CVS 4 suppositories — — FDA listed —
Laxative 10 mg 70795-1010-01 GRAXCELL 100 suppositories — — FDA listed —
OneLAX 10 mg 71399-8460-02 AKRON 12 suppositories — — FDA listed —
Conlax 10 mg 72701-0102-04 Bliss 4 suppositories — — FDA listed —
Bisacodyl 10 mg 82568-0028-02 AARNA 12 suppositories — — FDA listed —
Bisacodyl 10 mg 83720-0550-25 Oncor 12 suppositories — — FDA listed —
Bisacodyl Laxative 10 mg 71457-0501-01 InvaDerm 102 suppositories — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2024
On the market since
Dec 2024
📍
2026
Currently FDA-listed
2 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Bisacodyl inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 8334LX7S21
    A solid fat derived from animal or vegetable sources, used as a coating agent and lubricant to help pills slide smoothly during manufacturing and protect the medicine from moisture and air.

1 inactive ingredient listed in the exact product block matched to this NDC.

The official label also statesInactive ingredient hard fat

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerRising Pharma Holdings, Inc.
FDA applicationM007.60 (OTC MONOGRAPH DRUG)
Labeler code57237
First marketedDec 2024
Product typeHuman Otc Drug
Portfolio525 products on file

More NDCs from Rising Pharma Holdings, Inc. labeler code 57237

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 Storage and Handling 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Ask a Doctor Before Use If 📄 When Using This Product 📄 Stop Use and Ask a Doctor If 🤰 If Pregnant or Breast-Feeding 📄 Keep Out of Reach of Children 📄 Other Information 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 19 words ▾

Use for relief of occasional constipation (irregularity) this product generally produces bowel movement in 15 minutes to 1 hour

⏱️ Dosage and Administration 54 words ▾

Directions adults and children 12 years of age and over 1 suppository in a single daily dose. Peel open plastic. Insert suppository well into rectum, pointed end first. Retain about 15 to 20 minutes children 6 to under 12 years 1/2 suppository in a single daily dose children under 6 years Do not use

⚠️ Warnings 5 words ▾

Warnings For rectal use only

📦 Storage and Handling 20 words ▾

Other information store at 20-25°C (68-77°F) if suppository softens prior to use, may be placed in refrigerator for short time

🧪 Active Ingredient 9 words ▾

Active ingredient (in each suppository) Bisacodyl USP, 10 mg

🧪 Inactive Ingredients 4 words ▾

Inactive ingredient hard fat

🎯 Purpose 3 words ▾

Purpose Stimulant Laxative

📄 Ask a Doctor Before Use If 25 words ▾

Ask a doctor before use if you have stomach pain, nausea or vomiting a sudden change in bowel habits that lasts more than 2 weeks

📄 When Using This Product 15 words ▾

When using this product you may experience stomach discomfort, faintness, rectal burning and mild cramps

📄 Stop Use and Ask a Doctor If 39 words ▾

Stop use and ask a doctor if you need to use a laxative product for longer than one week you have rectal bleeding or no bowel movement after using this product. These could be signs of a serious condition.

🤰 If Pregnant or Breast-Feeding 9 words ▾

If pregnant or breast-feeding, ask health professional before use.

📄 Keep Out of Reach of Children 19 words ▾

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

📄 Other Information 7 words ▾

TAMPER EVIDENT, INDIVIVIDUALLY SEALED FOR YOUR PROTECTION

📄 Questions or Comments 5 words ▾

Questions or Comments: Call 1-844-474-7464

📄 Package Label / Principal Display Panel 46 words ▾

NDC 57237-337-21 (3 blisters of 4 suppositories) Proctozone-B TM Bisacodyl (USP) 10 mg Suppositories MEDICATED LAXATIVE SUPPOSITORY Gentle, Predictable Relief DO NOT SWALLOW NDC 57237-337-04 (4 suppositories in 1 blister pack) Front Foil NDC 57237-337-04 (4 suppositories in 1 blister pack) Back Foil Proctozone-B-supp-01 Proctozone-B-supp-02 Proctozone-B-supp-03

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q3 2025 – Q1 2026 · 3 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
2.7K
Units reimbursed last 4 qtrs
47.9K
Gross reimbursed last 4 qtrs
$29.1K
Avg / prescription
$10.91
Avg / unit
$0.6082
Latest quarter Q1 2026
2.2KRx
Medicaid pays / ea
$0.6082
gross reimbursed
vs
NADAC / ea
$0.3197
acquisition cost
=
Spread
+$0.2885
+90% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
61% FFS 39% MCO
Fee-for-service · 1,623 Rx Managed care · 1,048 Rx
State Medicaid map
Alaska: no data reported AK Maine: 458 units · 32.8 per 100k residents ME Washington: 2,914 units · 37.3 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 7,468 units · 130 per 100k residents MN Wisconsin: no data reported WI Michigan: 1,552 units · 15.5 per 100k residents MI New York: 4,864 units · 24.9 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 2,878 units · 68.0 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 367 units · 2.9 per 100k residents IL Indiana: 1,430 units · 20.8 per 100k residents IN Ohio: 4,789 units · 40.6 per 100k residents OH Pennsylvania: 1,690 units · 13.0 per 100k residents PA New Jersey: no data reported NJ Massachusetts: 366 units · 5.2 per 100k residents MA California: 13,402 units · 34.4 per 100k residents CA Utah: no data reported UT Colorado: 667 units · 11.3 per 100k residents CO Nebraska: 514 units · 26.0 per 100k residents NE Missouri: 885 units · 14.3 per 100k residents MO Kentucky: 799 units · 17.7 per 100k residents KY West Virginia: no data reported WV Virginia: 211 units · 2.4 per 100k residents VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 977 units · 13.1 per 100k residents AZ New Mexico: no data reported NM Kansas: 254 units · 8.6 per 100k residents KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: 209 units · 20.3 per 100k residents DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 1,202 units · 3.9 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
2.4130
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Minnesota 130 /100k
2 Oregon 68.0 /100k
3 Ohio 40.6 /100k
4 Washington 37.3 /100k
5 California 34.4 /100k
6 Maine 32.8 /100k
7 Nebraska 26.0 /100k
8 New York 24.9 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
30 suppositories57237-0337-03 2,978 Rx · $45,766
12 suppositories this page57237-0337-21 2,671 Rx · $29,129
Drug total (last 4 qtrs): 5,649 Rx · 113,126 units · $74,895 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
← 57237-0333-01 · Rising 57237-0338-21 · Rising →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.